| scholarly article | Q13442814 |
| P50 | author | Jernej Šribar | Q59683280 |
| Ivana Jovčevska | Q87479318 | ||
| P2093 | author name string | Michael P Myers | |
| Serge Muyldermans | |||
| Jure Stojan | |||
| Mirjana Liovic | |||
| Radovan Komel | |||
| Igor Križaj | |||
| Alja Zottel | |||
| Neja Samec | |||
| P2860 | cites work | The epithelial-mesenchymal transition generates cells with properties of stem cells | Q24650786 |
| Infantile encephalopathy and defective mitochondrial DNA translation in patients with mutations of mitochondrial elongation factors EFG1 and EFTu | Q24680662 | ||
| Cell-penetrating anti-GFAP VHH and corresponding fluorescent fusion protein VHH-GFP spontaneously cross the blood-brain barrier and specifically recognize astrocytes: application to brain imaging | Q39325717 | ||
| In vitro analysis and in vivo tumor targeting of a humanized, grafted nanobody in mice using pinhole SPECT/micro-CT. | Q39692007 | ||
| Transport across the primate blood-brain barrier of a genetically engineered chimeric monoclonal antibody to the human insulin receptor | Q40881449 | ||
| Selection of suitable reference genes for expression analysis in human glioma using RT-qPCR. | Q41090596 | ||
| Glioma and glioblastoma - how much do we (not) know? | Q42578340 | ||
| Improvement of single domain antibody stability by disulfide bond introduction | Q43993709 | ||
| Differential screening of a human pancreatic adenocarcinoma lambda gt11 expression library has identified increased transcription of elongation factor EF-1 alpha in tumour cells | Q44418502 | ||
| Glioblastoma under Siege: An Overview of Current Therapeutic Strategies. | Q47553080 | ||
| A single-step procedure of recombinant library construction for the selection of efficiently produced llama VH binders directed against cancer markers. | Q54398883 | ||
| TUFM is a potential new prognostic indicator for colorectal carcinoma. | Q55056372 | ||
| Model selection in magnetic resonance imaging measurements of vascular permeability: Gadomer in a 9L model of rat cerebral tumor. | Q55471176 | ||
| Nanobody-derived nanobiotechnology tool kits for diverse biomedical and biotechnology applications | Q26738678 | ||
| The SWISS-MODEL workspace: a web-based environment for protein structure homology modelling | Q27860637 | ||
| UCSF Chimera--a visualization system for exploratory research and analysis | Q27860666 | ||
| WHAT IF: a molecular modeling and drug design program | Q27860734 | ||
| Nanobodies: natural single-domain antibodies | Q28287268 | ||
| A perspective on cancer cell metastasis | Q28307891 | ||
| Serverification of molecular modeling applications: the Rosetta Online Server that Includes Everyone (ROSIE) | Q28914729 | ||
| Protocol for micro-purification, enrichment, pre-fractionation and storage of peptides for proteomics using StageTips | Q29614831 | ||
| The evidence of glioblastoma heterogeneity | Q30300892 | ||
| ProBiS-ligands: a web server for prediction of ligands by examination of protein binding sites. | Q30362875 | ||
| Stability of endogenous reference genes in postmortem human brains for normalization of quantitative real-time PCR data: comprehensive evaluation using geNorm, NormFinder, and BestKeeper | Q30570648 | ||
| Selection of suitable housekeeping genes for expression analysis in glioblastoma using quantitative RT-PCR | Q33414428 | ||
| Preclinical screening of anti-HER2 nanobodies for molecular imaging of breast cancer | Q33866799 | ||
| Formulations for Intranasal Delivery of Pharmacological Agents to Combat Brain Disease: A New Opportunity to Tackle GBM? | Q34383339 | ||
| Generation of single domain antibody fragments derived from camelids and generation of manifold constructs | Q34386048 | ||
| TRIM28 and β-actin identified via nanobody-based reverse proteomics approach as possible human glioblastoma biomarkers | Q34566316 | ||
| Engineered antibody fragments and the rise of single domains | Q34650980 | ||
| Sequence and structure of VH domain from naturally occurring camel heavy chain immunoglobulins lacking light chains | Q34662422 | ||
| Expression of elongation factor (EF)-Tu is correlated with prognosis of gastric adenocarcinomas | Q35536040 | ||
| Cancer as a mitochondrial metabolic disease | Q35824628 | ||
| Current trends in targeted therapies for glioblastoma multiforme | Q35864226 | ||
| Differentially expressed proteins in glioblastoma multiforme identified with a nanobody-based anti-proteome approach and confirmed by OncoFinder as possible tumor-class predictive biomarker candidates | Q36370196 | ||
| Brain tumour stem cells | Q36488721 | ||
| Insights into the regulation of protein abundance from proteomic and transcriptomic analyses | Q36846022 | ||
| Glioblastoma multiforme: a review of where we have been and where we are going | Q37530934 | ||
| Immuno-imaging using nanobodies | Q37897404 | ||
| Molecular biology of glioma | Q38013704 | ||
| The roots of cancer: stem cells and the basis for tumor heterogeneity | Q38048655 | ||
| Glioblastoma and other malignant gliomas: a clinical review. | Q38160159 | ||
| Glioblastoma multiforme: a look inside its heterogeneous nature | Q38182805 | ||
| Nanobody-based products as research and diagnostic tools | Q38201856 | ||
| Current Studies of Immunotherapy on Glioblastoma | Q38262914 | ||
| Diagnostic and Therapeutic Biomarkers in Glioblastoma: Current Status and Future Perspectives. | Q38743138 | ||
| TUFM downregulation induces epithelial-mesenchymal transition and invasion in lung cancer cells via a mechanism involving AMPK-GSK3β signaling | Q38802165 | ||
| P4510 | describes a project that uses | ImageJ | Q1659584 |
| P433 | issue | 25 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | neoplastic stem cells | Q1638475 |
| P304 | page(s) | 17282-17299 | |
| P577 | publication date | 2018-04-03 | |
| P1433 | published in | Oncotarget | Q1573155 |
| P1476 | title | Glioblastoma-specific anti-TUFM nanobody for in-vitro immunoimaging and cancer stem cell targeting | |
| P478 | volume | 9 |
| Q95273152 | Anti-vimentin, anti-TUFM, anti-NAP1L1 and anti-DPYSL2 nanobodies display cytotoxic effect and reduce glioblastoma cell migration |
| Q92662652 | Antibodies for the Treatment of Brain Metastases, a Dream or a Reality? |
| Q98466240 | Nanobodies: Next Generation of Cancer Diagnostics and Therapeutics |
| Q64956054 | Nanotechnology Meets Oncology: Nanomaterials in Brain Cancer Research, Diagnosis and Therapy. |
| Q90211941 | Single-Domain Antibodies as Therapeutic and Imaging Agents for the Treatment of CNS Diseases |
Search more.